Watch and wait policy in advanced neuroendocrine tumors: What does it mean?

Nicola Fazio1

  • 1Nicola Fazio, Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, 20141 Milan, Italy.

Insights

The "watch and wait" approach for neuroendocrine neoplasms (NENs) is not fully validated or standardized. While potentially useful for initial characterization in select patients, it is generally not recommended for avoiding anti-tumor treatment.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Neuroendocrine neoplasms (NENs) are rare, heterogeneous cancers with unpredictable clinical courses.
  • The
  • watch and wait
  • (W and W) strategy involves observing NENs without immediate anti-tumor therapy.
  • W and W is used due to rare cases of long-term NEN stability, but lacks validation and standardization.

Discussion:

  • Current guidelines mention W and W, but it has not been rigorously investigated or validated.
  • Clinical application of W and W varies significantly in imaging and assessment protocols.
  • The heterogeneity of NENs makes predicting their behavior challenging.

Key Insights:

  • Delaying initial therapy with W and W may be justified for a few weeks in asymptomatic, low-grade NEN patients to optimize treatment strategy.
  • W and W is difficult to justify with the intent to completely avoid anti-tumor treatment.
  • NENs can progress even with favorable biology, and effective, low-toxicity treatments like somatostatin analogs are available.

Outlook:

  • Further research is needed to validate and standardize the W and W approach for NENs.
  • Clearer guidelines are required for the appropriate application of W and W in NEN management.
  • Future strategies should balance observation with timely, effective therapeutic interventions for NENs.

Related Concept Videos